Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect and safety of semaglutide 7.2 mg once weekly in adults with obesity
2022-000790-94Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing Semaglutide 7.2 mg once weekly with Placebo once weekly (2 arms). Primary endpoint: Relative change in body weight. Started Sep 2022; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on 2022-000790-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000790-94.